DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
DDP-225 is an investigational drug.
There have been 30 clinical trials for DDP-225. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2011.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and First Affiliated Hospital of Guangxi Medical University.
There are twelve US patents protecting this investigational drug and one hundred and forty-four international patents.
Recent Clinical Trials for DDP-225
|Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.||Chia Tai Tianqing Pharmaceutical Group Co., Ltd.||Phase 2|
|Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）.||Henan Cancer Hospital||Phase 2|
|Efficacy and Safety of Albumin Paclitaxel Combined With Cisplatin Chemoradiotherapy for Non-resectable Stage III NSCLC||Guizhou Medical University||N/A|
Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|DDP-225||Start Trial||Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidin- e for treating of urinary incontinence||Arachnova Therapeutics Ltd. (Jersey, GB)||Start Trial|
|DDP-225||Start Trial||4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder||Dynogen Pharmaceuticals, Inc. (Waltham, MA)||Start Trial|
|DDP-225||Start Trial||Substituted phenoxy thiazolidinediones as estrogen related receptor-.alpha. modulators||Janssen Pharmaceutica, NV (Beerse, BE)||Start Trial|
|DDP-225||Start Trial||Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-.alpha. modulators||Janssen Pharmaceutica N.V. (Beerse, BE)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|